Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Serious Risks Hypoglycemia (low blood sugar): Rare on its own, but a potential risk when combined with insulin or insulin-stimulating drugs
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
Clinical Studies Despite increasing preclinical evidences of the involvement of seleno-GPxs in cellular radiosensitivity, there is no such clinical trial reported yet that focused solely on examining the effects of seleno-GPxs for modulating the radiation response of normal and/or tumor tissues
A: Yes, but cold-chain management is critical
For the BPC-157 vs TB-500 comparison, see BPC-157 vs TB-500
US$ 23.54
US$ 28.80
US$ 23.31
US$ 21.46
US$ 28.05
US$ 23.06
US$ 20.39
US$ 26.63
US$ 27.20
US$ 27.96
